Hematology

ASH highlights five recommendations from other organizations.

Lee Greenberger, PhD, chief scientific officer, The Leukemia & Lymphoma Society, discusses new agents that were recently approved for multiple myeloma.

The FDA has approved bendamustine hydrochloride (Bendeka) injection for the treatment of chronic lymphocytic leukemia (CLL) or indolent B-cell non-Hodgkin lymphoma (NHL).

The CD38 monoclonal antibody daratumumab in combination with lenalidomide and dexamethasone proved to be safe and showed an 81% response rate in patients with relapsed or refractory multiple myeloma, according to research presented at the 2015 ASH Annual Meeting.

The kinase inhibitor Ibrutinib (Imbruvica) is a more effective frontline therapy than the traditional chemotherapy chlorambucil in treating older treatment-naïve patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL), reducing the risk of death by 84%.

The FDA has approved Empliciti (elotuzumab) in combination with Revlimid (lenalidomide) and dexamethasone for patients with multiple myeloma who have received one to three prior therapies.

Ninlaro (ixazomib) has been approved by the FDA in combination with Revlimid (lenalidomide) and dexamethasone as a treatment for patients with multiple myeloma who received at least one prior therapy.

The FDA granted an accelerated approval of the CD-38-targeted monoclonal antibody daratumumab (Darzalex)-the first monoclonal antibody to be approved for patients with multiple myeloma.

Children exposed to residential pesticides are at a higher risk of developing pediatric hematopoietic cancers, a new study has found.

Regardless of insurance status, patients with multiple myeloma can expect financial hardships-even those making over $100,000 a year, according to a study published online in Lancet Haematology.

A new study has found that nonbiological factors including marital status, county-level income, and insurance status may also affect the chances of survival among young patients with acute myelogenous leukemia (AML).

David Carbone, MD, PhD, a survivor of lymphoma and director, James Thoracic Center, The Ohio State University Comprehensive Cancer - The James, discusses pain management in the context of being a patient and a physician.

Amanda Yopp, NP, Clinical Nurse Educator, Takeda Oncology, discusses the challenges with treating patients with multiple myeloma.

Kim Noonan, MS, RN, ANP, AOCN, chief nurse practitioner, Center for Neuro-Oncology, Dana-Farber Cancer Institute, discusses the challenges of treating patients with multiple myeloma.

A navigator-designed, proactive, weekly, telephone support call to help patients with blood cancers manage their symptoms between appointments was able to significantly reduce unplanned hospitalizations at a Colorado cancer center.

A new study has found that patients with lower vitamin D levels prior to treatment for follicular lymphoma are more likely to die or relapse from the disease earlier than patients with adequate vitamin D levels in their blood.

The FDA has approved deferasirox (Jadenu) for the treatment of chronic iron overload, a condition that can affect patients with myelodysplastic syndromes (MDS), sickle cell disease, and thalassemia.

Steven M. Horwitz, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses some new treatments on the horizon for T-cell lymphoma.

Shuo Ma, MD, PhD, assistant professor at Northwestern University in the Robert H. Lurie Comprehensive Cancer Center, discusses some of the side effects that come with new agents approved for the treatment of non-Hodgkin Lymphoma.

The FDA's approval of panobinostat (Farydak) for multiple myeloma, the first histone deacetylase (HDAC) inhibitor to be approved in this space, provides a new option and new hope for patients with this disease, Walter M. Capone, President and Chief Executive Officer of the Multiple Myeloma Research Foundation, said.

Clinicians who treat patients with multiple myeloma have witnessed a sea change in the past 15 years.

Michael Mauro, MD, hematologist and leader of the Myeloproliferative Neoplasms Program, Leukemia Service at Memorial Sloan Kettering Cancer Center, explains why some patients with CML don't adhere to their medication.

The year 2014 was distinguished by dramatic progress in cancer care, perhaps nowhere more so than in the treatment of blood cancers.

Rami S. Komrokji, MD, clinical director, Hematologic Malignancies, Moffitt Cancer Center, discusses the risk factors for developing myelodysplastic syndromes(MDS).

The FDA has approved lenalidomide (Revlimid) plus dexamethasone in newly diagnosed patients with multiple myeloma based on findings from the phase III FIRST trial.